Comparative Efficacy of Saroglitazar and Pioglitazone in Nonalcoholic Fatty Liver Disease Patients: A Bayesian Network Meta-analysis

吡格列酮 非酒精性脂肪肝 荟萃分析 医学 内科学 脂肪肝 内分泌学 疾病 2型糖尿病 糖尿病
作者
Binayak Sinha,Samit Ghosal,Debasis Datta
标识
DOI:10.4103/ijdt.ijdt_10_24
摘要

Abstract Background and Aims: Nonalcoholic fatty liver disease (NAFLD) is associated with metabolic syndrome. Two drugs, saroglitazar (S) and pioglitazone (P), are known to have beneficial effects on metabolic syndrome. This Bayesian network meta-analysis (NMA) was conducted to compare the relative efficacy of these two drugs in NAFLD patients. Materials and Methods: An electronic search of the Cochrane Library database yielded 12 randomized prospective studies for this NMA. R version 4.2.3 (64-bit) and Comprehensive Meta-Analysis Version 4 were used to analyze the data. Selection bias was screened with a funnel plot, and publication bias was assessed using the Cochrane risk of bias tool. The standardized mean difference (SMD) was used as an effect size estimate, and the surface under the cumulative ranking curve (SUCRA) value was used to rank S and P in comparison to placebo. Results: This NMA was conducted on a pooled population of 930 patients (379 receiving P, 159 receiving S, and 392 receiving placebo) diagnosed with NAFLD either by liver biopsy or radiologically along with transaminase estimation. S (alanine transaminase [ALT] [SMD −4.28, 95% confidence interval (CI) −7.46–−1.02], aspartate transaminase [AST] [SMD − 2.28, 95% CI −3.93–−0.62], and GGT [SMD −4.37, 95% CI − 7.43–−1.30]) and P (ALT [SMD −0.50 95% CI − 0.66–−0.34], AST [SMD − 0.42 95% CI − 0.59–−0.25], and GGT [SMD −1.42, 95% CI − 2.44–−0.41]) showed comparable improvement in inflammatory markers and the SUCRA score between the S and P groups, respectively. There was an impressive improvement in the NAS score by a ≥ 2-point reduction in both the saroglitazar (SMD −0.59, 95% CI − 0.98–−0.20) and the pioglitazone groups (SMD −0.49, 95% CI − 0.83–−0.15), and the SUCRA scores were comparable (0.80 for the S group versus 0.67 for the P group). P and S could not be compared with SUCRA values in view of significant heterogeneity differences concerning steatosis and lobular inflammation. S (SMD −0.77 95% CI − 1.16–−0.38) and P (SMD − 0.54, 95% CI −0.78–−0.30) were comparable in the improvement of hepatic ballooning (0.89 for the S group versus 0.60 for the P group). Conclusion: The efficacy of saroglitazar in improving hepatic markers and prominent biopsy parameters in NAFLD patients is comparable to that of pioglitazone.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
我是老大的应助被沉静的藏花采纳,获得10
1秒前
QWERT完成签到,获得积分10
1秒前
1秒前
2秒前
Verritis发布了新的文献求助10
2秒前
万能图书馆的应助被lyn123采纳,获得10
2秒前
黑米粥发布了新的文献求助200
2秒前
无敌的ybk完成签到,获得积分20
3秒前
3秒前
111发布了新的文献求助10
3秒前
Akim的应助被soleil采纳,获得10
3秒前
baiyz完成签到,获得积分10
4秒前
4秒前
5秒前
香香香发布了新的文献求助10
5秒前
甜橙完成签到 ,获得积分10
5秒前
66666完成签到,获得积分10
5秒前
6秒前
6秒前
6秒前
zsda完成签到,获得积分10
6秒前
6秒前
7秒前
homie发布了新的文献求助10
8秒前
呆萌尔风发布了新的文献求助20
8秒前
彭于晏的应助被zyyy采纳,获得30
8秒前
科研怪才完成签到,获得积分20
10秒前
小懒猪完成签到,获得积分10
10秒前
cc发布了新的文献求助10
10秒前
10秒前
科研通AI6.2的应助被phonon采纳,获得30
11秒前
鲸鱼完成签到,获得积分10
11秒前
12秒前
Hello的应助被Cope采纳,获得10
13秒前
ding的应助被Lachryz采纳,获得10
14秒前
14秒前
情怀的应助被窥荷采纳,获得10
15秒前
科研怪才发布了新的文献求助30
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187592
求助须知:如何正确求助?哪些是违规求助? 9575705
关于积分的说明 21842471
捐赠科研通 7785407
什么是DOI,文献DOI怎么找? 3435057
关于科研通互助平台的介绍 2559461
邀请新用户注册赠送积分活动 2481952